Literature DB >> 12765980

Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children.

Antonio Carroccio1, Giuseppe Iacono, Mario Cottone, Lidia Di Prima, Fabio Cartabellotta, Francesca Cavataio, Calogero Scalici, Giuseppe Montalto, Gaetana Di Fede, GiovamBattista Rini, Alberto Notarbartolo, Maurizio R Averna.   

Abstract

BACKGROUND: Fecal calprotectin (FC) has been proposed as a marker of inflammatory bowel disease (IBD), but few studies have evaluated its usefulness in patients with chronic diarrhea of various causes. We evaluated the diagnostic accuracy of a FC assay in identifying "organic" causes of chronic diarrhea in consecutive adults and children.
METHODS: We consecutively enrolled 70 adult patients (30 males, 40 females; median age, 35 years) and 50 children (20 males, 30 females; median age, 3.5 years) with chronic diarrhea of unknown origin. All patients underwent a complete work-up to identify the causes of chronic diarrhea. FC was measured by ELISA.
RESULTS: In adult patients, FC showed 64% sensitivity and 80% specificity with 70% positive and 74% negative predictive values for organic causes. False-positive results (8 of 40 cases) were associated with the use of aspirin (3 cases) or nonsteroidal antiinflammatory drugs (1 case) and with the presence of concomitant liver cirrhosis (3 cases). False-negative results mainly included patients suffering from celiac disease (5 cases). Patients with IBD (9 cases) were identified with 100% sensitivity and 95% specificity. In pediatric patients, sensitivity was 70%, specificity was 93%, and positive and negative predictive values were 96% and 56%. False-negative results (11 of 35 cases) were associated mainly with celiac disease (6 cases) or intestinal giardiasis (2 cases).
CONCLUSIONS: FC assay is an accurate marker of IBD in both children and adult patients. In adults, false negatives occur (e.g., in celiac disease) and false-positive results are seen in cirrhosis or users of nonsteroidal antiinflammatory drugs. Diagnostic accuracy is higher in children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12765980     DOI: 10.1373/49.6.861

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  57 in total

1.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  T Kaiser; J Langhorst; H Wittkowski; K Becker; A W Friedrich; A Rueffer; G J Dobos; J Roth; D Foell
Journal:  Gut       Date:  2007-08-03       Impact factor: 23.059

2.  Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.

Authors:  Zhuo Yang; Nick Clark; K T Park
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-21       Impact factor: 11.382

3.  Stability of the maternal gut microbiota during late pregnancy and early lactation.

Authors:  Ted Jost; Christophe Lacroix; Christian Braegger; Christophe Chassard
Journal:  Curr Microbiol       Date:  2013-11-21       Impact factor: 2.188

Review 4.  The Costs of Living Together: Immune Responses to the Microbiota and Chronic Gut Inflammation.

Authors:  Lucas J Kirschman; Kathryn C Milligan-Myhre
Journal:  Appl Environ Microbiol       Date:  2019-05-02       Impact factor: 4.792

Review 5.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

6.  Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation.

Authors:  Raffaele Pezzilli; Alessandra Barassi; Antonio M Morselli-Labate; Lorenzo Fantini; Paola Tomassetti; Davide Campana; Riccardo Casadei; Sergio Finazzi; Gianvico Melzi d'Eril; Roberto Corinaldesi
Journal:  J Gastroenterol       Date:  2007-09-25       Impact factor: 7.527

Review 7.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

8.  Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease.

Authors:  Michael Wagner; Christer G B Peterson; Peter Ridefelt; Per Sangfelt; Marie Carlson
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

Review 9.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

10.  Dynamic change of fecal calprotectin in very low birth weight infants during the first month of life.

Authors:  Qing Yang; P Brian Smith; Ronald N Goldberg; C Michael Cotten
Journal:  Neonatology       Date:  2008-09-11       Impact factor: 4.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.